Lïc Guillevin

Summary

Country: France

Publications

  1. ncbi [Intravenous immunoglobulins: therapeutic indications]
    L Mouthon
    Universite Paris Descartes, Groupe Hospitalier Cochin Saint Vincent De Paul, Service de Medecine Interne, Centre de Référence Vascularites et Sclérodermies, AP HP, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14 75, France
    Presse Med 34:1166-75. 2005
  2. ncbi Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Paris Cedex 14, France
    Rheumatology (Oxford) 51:460-7. 2012
  3. ncbi Valvular involvement in ANCA-associated systemic vasculitis: a case report and literature review
    Chloé Lacoste
    Assistance Publique Hopitaux de Paris AP HP, Department of Internal Medicine, Ambroise Pare Hospital, 9, avenue Charles de Gaulle, 92100, Boulogne Billancourt, France
    BMC Musculoskelet Disord 12:50. 2011
  4. ncbi Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor ? pathway in patients with systemic sclerosis
    Guillaume Bussone
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, 8 rue Mechain, F 75014 Paris, France
    Arthritis Res Ther 13:R74. 2011
  5. ncbi Vasculopathy and pulmonary arterial hypertension
    L Guillevin
    Service de Medecine Interne, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, Paris, France
    Rheumatology (Oxford) 48:iii54-7. 2009
  6. ncbi [Indications for immunoglobulins. Recommendations of CEDIT of AP-HP in 2006]
    L Guillevin
    Groupe d experts sur les immunoglobulines du Comité d évaluation et de diffusion des innovations technologiques CEDIT, Paris, France
    Rev Med Interne 28:1-3. 2007
  7. ncbi Indications for biotherapy in systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, French Vasculitis Study Group, Centre de Référence Vascularites et Sclérodermie, Hopital Cochin, Universite Paris Descartes, Paris, France
    Clin Rev Allergy Immunol 32:85-96. 2007
  8. ncbi Vasculitis: mechanisms involved and clinical manifestations
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, rue du Faubourg Saint Jacques, F 75014 Paris, France
    Arthritis Res Ther 9:S9. 2007
  9. ncbi [Treatment of ANCA associated systemic necrotizing vasculitides]
    Loic Guillevin
    Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Bull Acad Natl Med 192:1175-87; discussion 1188. 2008
  10. ncbi Indication for plasma exchange for systemic necrotizing vasculidities
    Loic Guillevin
    Department of Internal Medicine, Referral Center for Rare Diseases, Vasculitis and Scleroderma, Hopital Cochin, AP HP, Université de Paris René Descartes, 27, rue du Faubourg Saint Jacques, Paris, France
    Transfus Apher Sci 36:179-85. 2007

Collaborators

Detail Information

Publications79

  1. ncbi [Intravenous immunoglobulins: therapeutic indications]
    L Mouthon
    Universite Paris Descartes, Groupe Hospitalier Cochin Saint Vincent De Paul, Service de Medecine Interne, Centre de Référence Vascularites et Sclérodermies, AP HP, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14 75, France
    Presse Med 34:1166-75. 2005
    ..Its mechanisms of action are multiple, complex, and not yet well elucidated. Adverse effects are only rarely associated with IVIg. They are well tolerated, and the risk of transmission of infectious agents appears only theoretical...
  2. ncbi Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Paris Cedex 14, France
    Rheumatology (Oxford) 51:460-7. 2012
    ..This study was undertaken to describe SRC characteristics, prognosis and outcome, and evaluate the responsibility of CSs in its occurrence...
  3. ncbi Valvular involvement in ANCA-associated systemic vasculitis: a case report and literature review
    Chloé Lacoste
    Assistance Publique Hopitaux de Paris AP HP, Department of Internal Medicine, Ambroise Pare Hospital, 9, avenue Charles de Gaulle, 92100, Boulogne Billancourt, France
    BMC Musculoskelet Disord 12:50. 2011
    ..Antineutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitides have a variety of presentations, but cardiac valvular involvement is rarely diagnosed and its management is not established...
  4. ncbi Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor ? pathway in patients with systemic sclerosis
    Guillaume Bussone
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, 8 rue Mechain, F 75014 Paris, France
    Arthritis Res Ther 13:R74. 2011
    ..In this work, we aimed to identify new target autoantigens in SSc patients...
  5. ncbi Vasculopathy and pulmonary arterial hypertension
    L Guillevin
    Service de Medecine Interne, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, Paris, France
    Rheumatology (Oxford) 48:iii54-7. 2009
    ..Future therapeutic approaches may include rituximab, plasma exchanges, the TNF antagonist infliximab and haematopoietic stem cell transplantation...
  6. ncbi [Indications for immunoglobulins. Recommendations of CEDIT of AP-HP in 2006]
    L Guillevin
    Groupe d experts sur les immunoglobulines du Comité d évaluation et de diffusion des innovations technologiques CEDIT, Paris, France
    Rev Med Interne 28:1-3. 2007
    ....
  7. ncbi Indications for biotherapy in systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, French Vasculitis Study Group, Centre de Référence Vascularites et Sclérodermie, Hopital Cochin, Universite Paris Descartes, Paris, France
    Clin Rev Allergy Immunol 32:85-96. 2007
    ..Results of international ongoing trials will determine whether the agents may also have a place as first-line treatment...
  8. ncbi Vasculitis: mechanisms involved and clinical manifestations
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, rue du Faubourg Saint Jacques, F 75014 Paris, France
    Arthritis Res Ther 9:S9. 2007
    ....
  9. ncbi [Treatment of ANCA associated systemic necrotizing vasculitides]
    Loic Guillevin
    Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Bull Acad Natl Med 192:1175-87; discussion 1188. 2008
    ..New strategies are needed to prevent relapses and to limit adverse drug effects...
  10. ncbi Indication for plasma exchange for systemic necrotizing vasculidities
    Loic Guillevin
    Department of Internal Medicine, Referral Center for Rare Diseases, Vasculitis and Scleroderma, Hopital Cochin, AP HP, Université de Paris René Descartes, 27, rue du Faubourg Saint Jacques, Paris, France
    Transfus Apher Sci 36:179-85. 2007
    ..Although PE does not improve survival, their adjunction to corticosteroids and immunosuppressants for patients with alveolar hemorrhage could also limit the severity of this severe manifestation...
  11. ncbi [Classification of systemic vasculatides]
    Loic Guillevin
    Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:845-53. 2007
    ....
  12. ncbi [Classification of systemic vasculitides]
    Loic Guillevin
    Service de Medecine Interne, Centre de référence maladies rares Vascularites et Sclérodermies systémiques, Hopital Cochin, université Paris V René Descartes, Paris
    Rev Prat 58:480-6. 2008
    ....
  13. ncbi Clinical trials on systemic necrotizing vasculitides
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, rue du Faubourg Saint Jacques, Paris Cedex 14, France
    Presse Med 39:653-9. 2010
    ..Some of the latter have achieved promising effects, for example, anti-tumor necrosis factor-alpha and anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials...
  14. ncbi [Pulmonary involvement in systemic scleroderma]
    Loic Guillevin
    Medecine Interne, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Bull Acad Natl Med 195:79-90; discussion 90-2. 2011
    ..This paper focuses on the most significant disease manifestations and current therapeutic options...
  15. ncbi [Treatment of systemic vasculitides]
    Lïc Guillevin
    Service de Medecine Interne, Centre de référence maladies rares Vascularites et Sclérodermies systémiques, Hopital Cochin, université Paris V René Descartes, Paris
    Rev Prat 58:541-4. 2008
    ..The treatment duration of non-infectious vasculitides is typically 18 to 24 months. The improvement in prognosis is due to the treatment as well as to anti-infectious prophylaxis and careful management of potential complications...
  16. ncbi Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris, Paris, France
    Isr Med Assoc J 10:89-91. 2008
    ..Some of them (e.g., anti-tumor necrosis factor-alpha and anti-CD20 monoclonal antibodies) have achieved promising results and are now often used to treat severe cases...
  17. ncbi [What is the outcome of cardiac arrest survivors?]
    Jerome Fichet
    Service de Reanimation Medicale, Hopital Cochin AP HP, 75679 Paris Cedex 14, France
    Presse Med 39:694-700. 2010
    ..The << minor >> cerebral sequels remain unknown and their impact on quality of life needs further attention...
  18. ncbi Advances in the treatments of systemic vasculitides
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, 27 rue du Faubourg Saint Jacques, Paris, France
    Clin Rev Allergy Immunol 35:72-8. 2008
    ..The strategies that improve patient's outcome are discussed in the light of the prospective trials organized by international research groups...
  19. ncbi [Treatment of ANCA-associated vascularitides]
    Loic Guillevin
    Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:922-7. 2007
    ..These biologics must be prescribed extremely cautiously and only in trial settings, especially in view of the adverse effects, few but severe, recently been reported with them...
  20. ncbi Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
    ..High amprenavir and lopinavir concentrations in these patients might explain why plasma concentrations and the phenotypic IQ have poor predictive value...
  21. ncbi [Twenty-seven years' activities of the French vasculitis study group (FVSG)]
    L Guillevin
    , , , , AP-HOP, , 27 rue du Faubourg-Saint-Jacques, 75014 Paris, France
    Rev Med Interne 28:S263-5. 2007
  22. ncbi Brachial plexopathy associated with diffuse edematous scleroderma
    L Mouthon
    Department of Internal Medicine, Hôpital Avicenne and Paris Nord University, 125, route de Stalingrad, 93000 Bobigny, France
    Ann Med Interne (Paris) 151:303-5. 2000
    ..After six months intravenous pulse cyclophosphamide therapy, dramatic improvement of skin and neurological involvement was observed...
  23. ncbi Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients
    B Brihaye
    French Vasculitis Study Group, Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris 5 Rene Descartes, Paris, France
    Clin Exp Rheumatol 25:S23-7. 2007
    ..But the frequency of and time to responses to rituximab, and its effects on various clinical WG manifestations remain to be thoroughly evaluated...
  24. ncbi Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale
    L Mouthon
    Department of Internal Medicine, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 66:1651-5. 2007
    ..To develop and assess the reliability and construct validity of a scale assessing disability involving the mouth in systemic sclerosis (SSc)...
  25. ncbi HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is
    Véronique Avettand-Fenoel
    AP HP, CHU Necker Enfants Malades, Laboratoire de Virologie, Paris, France
    J Clin Virol 42:399-404. 2008
    ..Previously, HIV-DNA levels have sometimes been reported by other means: copies/10(6) CD4(+)T cells, reflecting the proportion of infected cells; or copies/mL whole blood, reflecting the global blood reservoir size...
  26. ncbi Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura
    Evangeline Pillebout
    Nephrology Department, Hopital Saint Louis, 1 av C Vellefaux, Paris, France
    Kidney Int 78:495-502. 2010
    ..The small population size of our study does not permit definitive conclusions; however, we suggest that treatment of adults with severe HSP by adding cyclophosphamide provides no benefit compared with steroids alone...
  27. ncbi High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis
    Y Allanore
    Rene Descartes University, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 58:284-91. 2008
    ..To evaluate predictors of pulmonary arterial hypertension (PAH) in a prospective cohort of patients with systemic sclerosis (SSc)...
  28. ncbi [Tobacco reduction in a prison of France]
    L Harcouet
    Service de Pharmacie, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris 5 Rene Descartes, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Rev Med Interne 29:357-63. 2008
    ..The objective is to study this efficacy in prison as well as motivations to reduce and influence of socioeconomic conditions and other addictions in prisoners' aspiration to stop smoking...
  29. ncbi Vasculitis restricted to the lower limbs: a clinical and histopathological study
    M Khellaf
    Service de Medecine Interne, Hopital Henri Mondor, Universite Paris XII, France
    Ann Rheum Dis 66:554-6. 2007
    ..Rare cases of vasculitis restricted to the lower limbs have been reported, but the characteristics, outcome and response to treatment of this entity are not well known...
  30. ncbi Vasculitides secondary to infections
    C Pagnoux
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris 5, Paris, France
    Clin Exp Rheumatol 24:S71-81. 2006
    ..In the near future, newer antiviral agents will probably also have their place in the therapeutic armamentarium for these patients...
  31. ncbi Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
    M Humbert
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Respir J 36:549-55. 2010
    ..Survival of idiopathic, familial and anorexigen-associated PAH can be characterised by means of a novel risk-prediction equation using patients' characteristics at diagnosis...
  32. ncbi Antigen inhalation as a triggering factor in systemic small-sized-vessel vasculitis. Four cases
    L Mouthon
    Service de Medecine Interne, Hopital Avicenne, Universite Paris Nord, Bobigny, Cedex, France
    Ann Med Interne (Paris) 152:152-6. 2001
    ..Identifying such etiological factors could improve our understanding of the pathogenesis of systemic vasculitides and prevent relapses due to similar antigenic exposure...
  33. ncbi Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients
    J Marmursztejn
    Department of Cardiology, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris, France
    Clin Exp Rheumatol 27:S70-6. 2009
    ..To examine the diagnostic contributions of cardiac magnetic resonance imaging (CMRI) with delayed-enhancement (DE) in patients with Churg-Strauss syndrome (CSS)...
  34. ncbi Churg-Strauss syndrome in two patients receiving montelukast
    P Guilpain
    Department of Internal Medicine, , Assistance Publique, , , 125 route de Stalingrad, 93009 Bobigny Cedex, France
    Rheumatology (Oxford) 41:535-9. 2002
    ..The other hypotheses are a coincidence or a direct adverse effect of the antileukotriene. Long-term data on these drugs are lacking and leukotriene's role in vasculitis remains to be elucidated...
  35. ncbi Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
    J J Laurichesse
    Laboratoire de Recherche en Pathologie Infectieuse, Universite Paris 7, Paris, France
    HIV Med 11:239-44. 2010
    ..The aim of the study was to determine whether the chemokine (C-C motif) receptor 5 (CCR5) Delta32 deletion is associated with long-term response to combination antiretroviral treatment (cART) in HIV-1-infected patients...
  36. ncbi Lack of association between B19 or V9 erythrovirus infection and ANCA-positive vasculitides: a case-control study
    A Eden
    Department of Internal Medicine, Hopital Avicenne, Universite Paris Nord, Unité de Recherche Clinique et Thérapeutique EA 3409, Bobigny, France
    Rheumatology (Oxford) 42:660-4. 2003
    ..To examine the potential association of human B19 or V9 erythrovirus infection and onset of ANCA-positive vasculitides...
  37. ncbi Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  38. ncbi A descriptive and prognostic study of systemic sclerosis-associated myopathies
    B Ranque
    Universite Paris Descartes, UPRES EA 4058, Department of Internal Medicine, French National Reference Center for Systemic Sclerosis and Necrotizing Vasculitides, Hopital Cochin, Assistance Publique des Hopitaux de Paris, Paris, France
    Ann Rheum Dis 68:1474-7. 2009
    ..To describe the clinical characteristics and muscle pathological features of patients with systemic sclerosis (SSc) and myopathy and analyse their impact on muscle outcome...
  39. ncbi Cardiac involvement in small and medium-sized vessel vasculitides
    C Pagnoux
    Department of Internal Medicine, Hopital Cochin, Universite Paris, Paris, France
    Lupus 14:718-22. 2005
    ..This regimen has dramatically improved the overall prognosis of affected patients...
  40. ncbi Indications for plasma exchange in systemic lupus erythematosus in 2005
    C Pagnoux
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Rene Descartes, Paris, France
    Lupus 14:871-7. 2005
    ....
  41. ncbi Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjogren syndrome: a case-control study
    V Le Guern
    Department of Internal Medicine, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 69:132-7. 2010
    ....
  42. ncbi Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis
    L Mouthon
    Paris Descartes University, Department of Internal Medicine, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 69:214-7. 2010
    ..To assess the impact of digital ulcers (DUs) on disability and health-related quality of life (HRQoL) in systemic sclerosis (SSc)...
  43. ncbi [Cerebral vasculitis]
    C Pagnoux
    , , , , , Paris
    Rev Neurol (Paris) 164:F109-17. 2008
  44. ncbi Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?
    A Mahr
    Department of Internal Medicine, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 65:826-8. 2006
    ..To investigate the relation between temporal artery biopsy (TAB) length and diagnostic sensitivity for giant cell arteritis...
  45. ncbi High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients
    Y Allenbach
    The National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Department of Internal Medicine, Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Ann Rheum Dis 68:564-7. 2009
    ..To determine the frequency and risk factors of venous thromboembolic events (VTE) in Wegener's granulomatosis (WG), microscopic polyangiitis (MPA) and, the so far unstudied, Churg-Strauss syndrome (CSS) and polyarteritis nodosa (PAN)...
  46. ncbi Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients
    L Josselin
    Department of Internal Medicine, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 67:1343-6. 2008
    ..However, its safety and ability to induce and maintain remission over the long term remain unknown...
  47. ncbi HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    B Roquebert
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:914-20. 2008
    ..We investigated the in vitro phenotypic susceptibility of HIV-2 isolates from integrase inhibitor (INI)-naive patients to INIs and its relation to HIV-2 integrase gene polymorphism...
  48. ncbi Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19)
    E Rosenthal
    Department of Internal Medicine, Archet Hospital Centre, University of Nice Sophia Antipolis, Nice, France
    HIV Med 10:282-9. 2009
    ..More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005...
  49. ncbi The spectrum of reactive hemophagocytic syndrome in systemic lupus erythematosus
    T Papo
    Internal Medicine Unit, Pitie Salpetiere Hospital, Paris, France
    J Rheumatol 26:927-30. 1999
    ....
  50. ncbi [Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis]
    C Georges
    Service de Medecine Interne, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75475 Paris 10, France
    Rev Med Interne 25:16-21. 2004
    ....
  51. ncbi [Infections and lymphoma during prolonged immunosuppression in vascular diseases]
    L Guillevin
    , , Paris, France
    Rev Med Interne 26:35-8. 2005
  52. ncbi Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients
    L Teixeira
    Internal Medicine Department and Reference Center for Vasculitis and Systemic Sclerosis, Cochin Hospital, Assistance Publique Hopitaux de Paris, and UPRES EA 4058, Paris Descartes University, Faculty of Medicine, France
    Ann Rheum Dis 67:110-6. 2008
    ..To describe presentation and outcome of patients with scleroderma renal crisis (SRC)...
  53. ncbi Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up
    A Mahr
    , , , 125, route de Stalingrad, 93009 Bobigny Cedex, France
    Rheumatology (Oxford) 40:492-8. 2001
    ..Conversely, univariate analysis indicated that patients with ENT involvement tended to have a better outcome, suggesting a more benign evolution of granulomatous disease compared with more aggressive vasculitis...
  54. ncbi Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients
    P Bartolucci
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Université Descartes Paris 5, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Lupus 16:817-22. 2007
    ..9 to 1.2. A regimen combining CS, cyclophosphamide and PE is effective against severe NPSLE, with acceptable toxicity...
  55. ncbi Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex
    S Abgrall
    , , Nord, Bobigny, France
    J Rheumatol 28:631-3. 2001
    ..Our cases appear to be isolated vasculitic neuropathies, with vasculitis strictly limited to the peripheral neuromuscular system without nonspecific clinical and/or biological systemic involvement...
  56. ncbi Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients
    O Benveniste
    , , and Laboratoire de Neuropathologie, , Paris, France
    J Immunol 167:3521-9. 2001
    ..Moreover, this method may be helpful for the differential diagnosis of polymyositis and dermatomyositis and for noninvasive follow-up of polymyositis patients...
  57. ncbi Successful treatment of thymoma-associated pure red cell aplasia with intravenous immunoglobulins
    C Larroche
    Department of Internal Medicine, Hopital Avicenne, Universite Paris Nord, Bobigny, France
    Eur J Haematol 65:74-6. 2000
    ..After failure of thymectomy, corticosteroids and octreotide, a complete durable remission was obtained after a single 5-d cycle of IVIG...
  58. ncbi Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension
    J Wipff
    Rene Descartes University, Medical Faculty, Rheumatology A Department, Cochin Hospital, AP HP, Paris, France
    Rheumatology (Oxford) 46:622-5. 2007
    ..A 6-base insertion in intron 7 (6bINS) of ENG has been reported to be associated with microvascular disturbance...
  59. ncbi Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population
    J Wipff
    Rheumatology A Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 65:1230-2. 2006
    ..38). The PTPN22*620W allele was also not associated with autoantibody patterns. Thus, the PTPN22*R620W polymorphism cannot be regarded as a genetic susceptibility factor for SSc in the French Caucasian population...
  60. ncbi [Treatment of systemic necrotizing vasculitis]
    L Guillevin
    , , , 125, rue de Stalingrad, 9300 Bobigny, France
    Rev Med Interne 23:554s-558s. 2002
  61. ncbi Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide
    K P Tiev
    Dept of Internal Medicine, Faculty of Medicine, Université Paris Pierre et Marie Curie, Hopital Saint Antoine, Paris, France
    Eur Respir J 30:26-30. 2007
    ....
  62. ncbi Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis
    A Servettaz
    Universite Paris Descartes, Faculte de Medecine, IFR Alfred Jost, Paris, France, and Service de Médecine Interne, Centre National de Référence Sclérodermie Vascularites, AP HP, Hopital Cochin, Paris, France
    Ann Rheum Dis 66:1202-9. 2007
    ..To investigate the role of reactive oxygen species (ROS) in the development of the various patterns of systemic sclerosis (SSc) and the mechanisms of ROS production by endothelial cells and fibroblasts...
  63. ncbi Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients
    C Charlier
    Department of Internal Medicine, Hopital Cochin, Universite Paris Descartes, Faculte de Medicine, UPRES EA 4058, Assistance Publique Hopitaux de Paris, Paris Cedex 14, France
    Ann Rheum Dis 68:658-63. 2009
    ..To characterise major infectious complications and analyse potential risk factors in patients with Wegener granulomatosis (WG)...
  64. ncbi [Endobronchial stenosis in Wegener's granulomatosis]
    B Hervier
    , , place Alexis-Ricordeau, 44093 Nantes Cedex, France
    Rev Med Interne 27:453-7. 2006
    ..Moreover general and local treatment must be given early (at the inflammatory stage). After this stage, the local treatments are difficult and not efficient...
  65. ncbi [Interstitial lung disease in systemic sclerosis]
    L Mouthon
    Service de Medecine Interne, Hopital Cochin, Centre de Référence pour la sclérodermie systémique, Assistance Publique Hôpitaux de Paris et Université Paris Descartes, Faculté de Médecine Paris Descartes, Paris, France
    Rev Mal Respir 24:1035-46. 2007
    ..Interstitial lung diseases (ILD) in systemic sclerosis (SSc) are mainly encountered in patients with diffuse disease although they may occur less frequently in patients with limited cutaneous disease...
  66. ncbi Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease
    B Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, Paris, France
    J Rheumatol 28:322-9. 2001
    ..To determine the usefulness of serum ferritin and glycosylated ferritin (GF) levels in diagnosing adult onset Still's disease (AOSD)...
  67. ncbi Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4-deficient patients with systemic lupus erythematosus (SLE)
    M A Dragon-Durey
    Service d Immunologie Clinique Biologique, Hopital Europeen Georges Pompidou, Paris, France
    Clin Exp Immunol 123:133-9. 2001
    ..Our results argue against a specific role for C4A gene deficiency in determining disease susceptibility among patients with SLE that are C4-deficient...
  68. ncbi The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study
    T Hauser
    Department of Internal Medicine, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Thorax 63:677-82. 2008
    ..A study was undertaken to investigate the relationship between the leucotriene receptor antagonist montelukast and the onset of CSS...
  69. ncbi A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis
    V Witko-Sarsat
    Institut National de la Santé et de la Recherche Médicale U507 and Department of Nephrology, Necker Hospital, Paris, France
    J Am Soc Nephrol 10:1224-33. 1999
    ..It was normal in type I-diabetes, a T cell-dependent autoimmune disease. It is proposed here that a high proportion of membrane PR3-positive neutrophils could favor the occurrence or the progression of chronic inflammatory diseases...
  70. ncbi Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia
    V Rieu
    Department of Internal Medicine, , , , 125 rue de Stalingrad, 93009 Bobigny Cedex, France
    Rheumatology (Oxford) 41:290-300. 2002
    ..CONCLUSION: Clinical manifestations of cryoglobulinaemia, except arthralgias, were comparable for HCV(+) and HCV(-) patients. When systemic manifestations are present, the prognosis is poor despite intensive or prolonged therapy...
  71. ncbi [Eosinophil granule cationic proteins: eosinophil activation markers]
    P Guilpain
    , , UPRES-EA 1833, Paris, France
    Rev Med Interne 27:406-8. 2006
    ..CONCLUSION: Eosinophil granule proteins are implicated in the occurrence of allergic diseases and Churg-Strauss syndrome. These proteins are activation markers of eosinophils and may be useful in clinical practice...
  72. ncbi Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit
    B A Cruz
    Department of Internal Medicine, , , , Bobigny, France
    Rheumatology (Oxford) 42:1183-8. 2003
    ....
  73. ncbi Knowledge, attitudes and vaccination coverage of healthcare workers regarding occupational vaccinations
    P Loulergue
    Universite Paris Descartes, Faculte de Medecine, INSERM, CIC BT 505, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Cochin Saint Vincent De Paul, Pôle de médecine, CIC de vaccinologie Cochin Pasteur, Paris, France
    Vaccine 27:4240-3. 2009
    ..The aim of this study was to evaluate knowledge regarding occupational vaccinations, HBV, varicella and influenza vaccination rates and attitudes towards influenza vaccine among HCWs...
  74. ncbi Factors influencing influenza-vaccination in adults under immunosuppressive therapy for a systemic inflammatory disease
    F Lanternier
    Pôle de médecine, Groupe Hospitalier Cochin Saint Vincent De Paul, AP HP, Universite Paris Descartes, Paris, France
    Med Mal Infect 39:247-51. 2009
    ..The aim of this study was to evaluate flu vaccination rates and influencing factors in patients with systemic inflammatory diseases...
  75. ncbi Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension
    M C Tamby
    Paris-Descartes University, Faculty of Medicine, Paris, France
    Eur Respir J 28:799-807. 2006
    ..Immunoglobulin G from patients with idiopathic pulmonary arterial hypertension or scleroderma-associated pulmonary arterial hypertension express distinct reactivity profiles with fibroblasts antigens, suggesting distinct target antigens...
  76. ncbi Clinical pictures of and therapeutic strategies for systemic vasculitides
    L Guillevin
    , , , , 27, rue du Faubourg Saint-Jacques, 75679 Paris 14, France
    Autoimmun Rev 3:S49-51. 2004
  77. ncbi Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis
    L Teixeira
    Department of Internal Medicine, , , 27, rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France
    Rheumatology (Oxford) 44:247-50. 2005
    ..In a clinical setting of Wegener's granulomatosis/TB mimicry, such combined reactivity would seem to be more suggestive of Wegener's granulomatosis...
  78. ncbi [Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (the ItinérAIR-Sclérodermie Study)]
    E Hachulla
    Service de Medecine Interne, CHRU Claude Huriez, Place de Verdun, 59037 Lille Cedex, France
    Rev Med Interne 25:340-7. 2004
    ..Its prevalence varies from 5% to 35% in the literature. A systematic yearly screening is recommended for early detection and management of PAH, but no precise algorithm is yet available...